trial

Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic

NCTId NCT00428350
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 120 (estimated)
Sponsored by AstraZeneca
Primary completion 2007-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
120 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2006-12
Primary completion
2007-09
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Quetiapine

Sponsors

AstraZenecaLead Sponsor

Investigators

2
Jon Zhu, MDStudy Director
Gang Wang, MDPrincipal Investigator

Sites

9 total
Guangzhou, ChinaHarbin, ChinaWuhan, ChinaNanjing, ChinaJinan, ChinaKunming, ChinaHangzhou, ChinaHuzhou, ChinaBeijing, China

Facts & assertions

4 sourced
Enrollment
120
Phase
PHASE4
Primary Completion Date
2007-09
Status
COMPLETED
relationships
The graph out of here
drug
Quetiapine
drug
lead_sponsor
AstraZeneca
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Jon Zhu, MD
person
Gang Wang, MD
person